🇺🇸 FDA
Patent

US 11337971

Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

granted A61KA61K31/485A61K31/496

Quick answer

US patent 11337971 (Dopamine D3 receptor selective antagonists/partial agonists and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue May 24 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K31/485, A61K31/496, A61P, A61P25/36